SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC
← catalyst calendarNCT07701070 · readout in 954 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Food and Drug Administration (FDA).
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
3,000estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-30 | estimated | When the study began enrolling |
| Primary completion | 2029-03-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Breast Cancer
Intervention
- Other: Blood sampling
Primary outcomes
what the primary-completion date above is the date OFPrevalence of ESR1 mutations in circulating tumour DNA
measured At baseline, approximately 3, 6, 9, 12, 15, and 18 months after initial testing
Emergence of ESR1 mutations during longitudinal ctDNA surveillance
measured At approximately 3, 6, 9, 12, 15, and 18 months after initial testing
Time to first detection of an ESR1 mutation
measured From first-line AI plus CDK4/6 inhibitor initiation to first ESR1 mutation detection
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed